Latest news and upcoming events
AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.
Bunnik, The Netherlands, 9 June 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both granted orphan designation status to recAP for the treatment of hypophosphatasia.
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications.
Ysios Capital achieves Certification under the Diversity VC Standard
Ysios Capital is the first specialized venture capital firm in life sciences globally and the first Spanish firm to achieve the Diversity VC Standard.
AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
Overall deal value is up to EUR 245 million.
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve
Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions
Adcendo Appoints Michael Pehl as Chief Executive Officer
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program.
Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ
This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.